The image contains six panels (A to F) depicting the effects of H I F i therapy in melanoma and prostate cancer models. Panel A shows a timeline for C 5 7 B L/6 mice injected with B 1 6 F 10 melanoma cells and treated with vehicle, H I F i (1.21 S 9 N or 3.2.16), anti-C T L A-4, or H I F i plus anti-C T L A-4. Panel B presents a line graph of mean tumor volumes over days post-inoculation, with different treatment groups indicated by distinct colors and symbols. The vertical axis represents tumor volume in cubic millimeters, and the horizontal axis represents days post-inoculation. Panel C shows Kaplan-Meier survival curves for the same treatment groups, with the vertical axis representing percent survival and the horizontal axis representing days post-inoculation. Panel D shows a similar timeline for C 57 B L/6 mice injected with D X 1 prostate cancer cells. Panel E presents a line graph of mean tumor volumes for these mice, with the same axes as Panel B. Panel F shows Kaplan-Meier survival curves for the prostate cancer model, with the same axes as Panel C. The graphs indicate that combination treatments with H I F i and anti-C T L A-4 result in reduced tumor volumes and improved survival rates compared to other treatments. All data is approximate.
Effect of HIFi therapy in melanoma and prostate cancer models. (A) C57BL/6 mice were injected subcutaneously with B16F10 melanoma cells and treated with vehicle, HIFi (1.21S9N or 3.2.16), α-CTLA-4, or HIFi + α-CTLA-4. (B) Mean tumor volumes are shown (mean + SD, n = 5). #P < 0.05 versus vehicle, **P < 0.005 versus α-CTLA-4 by two-way ANOVA with Tukey’s post-test. (C) Kaplan–Meier survival curves are shown. (D) C57BL/6 mice were injected with DX1 prostate cancer cells and treated with vehicle, HIFi, α-CTLA-4, or HIFi + α-CTLA-4. (E) Mean tumor volumes are shown (mean + SD, n = 5). ≠P < 0.05 versus vehicle, #P <0.05 versus vehicle, **P < 0.05 versus α-CTLA-4 by two-way ANOVA with Tukey’s post-test. (F) Kaplan–Meier survival curves are shown.